Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fatrisil is an antacid suspension developed and marketed by Oak-Faith Pharmaceutical Resources. It is a combination product containing magnesium trisilicate, aluminum hydroxide, and magnesium carbonate. The drug is indicated for the symptomatic relief of dyspepsia, heartburn, and hyperacidity associated with conditions such as peptic ulcers and gastritis. Its mechanism of action involves the direct neutralization of gastric hydrochloric acid, which increases the pH of the stomach contents and reduces the corrosive effect of acid on the gastric and esophageal mucosa. Additionally, magnesium trisilicate and aluminum hydroxide can provide a protective coating to the stomach lining and possess adsorbent properties that help mitigate gastric irritation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on magnesium trisilicate + aluminum hydroxide + magnesium carbonate.